IgA Nephropathy Diagnosis
IgA Nephropathy Diagnosis
IgA nephropathy is the commonest primary glomerular disease found on biopsy and one of the few kidney diseases that cannot be diagnosed from blood. This page sets out what the urine and blood tests can establish, what the biopsy adds that nothing else can, how the Oxford score is read, and which secondary causes must be excluded before the label is applied.
What blood and urine tests can and cannot establish
The non-invasive tests do most of the descriptive work: they say how much the kidney is leaking, how much filtration remains, and whether the immune system is generally activated. What they cannot do is name the disease, and being clear about that boundary prevents both over-investigation and false reassurance.
| Test | What it establishes | What it cannot establish |
|---|---|---|
| Urine microscopy | Whether the red cells are dysmorphic and whether casts are present — the signature of bleeding through a filter | Which nephritis. Dysmorphic cells and casts say glomerulonephritis; they do not say IgA |
| Protein-to-creatinine ratio | How much protein is being lost, and later whether treatment is working | The cause. Heavy proteinuria appears in many glomerular diseases |
| Serum creatinine and filtration rate | How much function remains, and — across several readings — the direction it is moving | How much is reversible. Function and scarring are not the same measurement |
| Serum IgA level | Very little in this disease | The diagnosis. It is normal in most patients with IgA nephropathy, which is why it is not part of the workup |
| Complement and autoantibodies | Whether another immunological disease — lupus in particular — is the better explanation | IgA nephropathy itself, in which complement is typically normal |
| Blood pressure measurement | Both a driver and a marker of progression, and the most treatable one | Anything about the underlying pathology |
A practical point about the protein measurement, because it decides treatment more often than any other single result: measure it more than once, and measure it when the person is well. Protein rises with infection, fever, heavy exercise and dehydration. Two or three values in quiet weeks are worth more than a single dramatic one, and the trajectory across them is what justifies or withholds immune therapy.
The biopsy: what it adds that nothing else can
A kidney biopsy takes one or two thin cores of tissue through a needle guided by ultrasound, almost always from the lower pole of one kidney. The tissue is then read in three ways, and each answers a different question: light microscopy shows the architecture — how much is inflamed and how much is scarred; immunofluorescence shows what is deposited and where, and it is the step that makes the diagnosis; electron microscopy localises the deposits at the level of the individual filter and excludes the conditions that mimic this one.
The diagnostic finding is dominant or codominant granular IgA in the mesangium, usually with complement and often with IgG in the same distribution. That single sentence separates IgA nephropathy from every other glomerular disease, and no blood test approximates it.
Because it is a procedure, it is worth stating plainly what is involved. Blood pressure is controlled and blood-thinning medicines are stopped for an agreed period beforehand; the biopsy is done under local anaesthetic with ultrasound guidance; and the patient lies flat and is monitored for several hours afterwards, usually staying in hospital for the rest of the day or overnight. The commonest complication is bleeding around the kidney, which is usually detected on the post-procedure scan and managed with observation. Serious complications are uncommon.
What is being weighed is not a risk against no risk. It is a short, well-managed procedure against the alternative — treating a young person with medicines that suppress immunity, on the assumption that the diagnosis is IgA nephropathy when it may be something else entirely. That asymmetry is why the biopsy is the central step of this page rather than the last refinement.
Reading the Oxford MEST-C score
The Oxford classification turns a biopsy report into a reproducible profile. Each letter is scored independently, and the value of the system is that two pathologists in different countries will largely agree — which is what allows risk to be discussed, compared and researched at all.
| Letter | Feature and its scores | What a higher score means for the plan |
|---|---|---|
| M | Mesangial hypercellularity, M0 or M1 | Confirms the disease rather than grading it; on its own it changes little |
| E | Endocapillary proliferation, E0 or E1 | Inflammation that is still potentially reversible — the feature that argues for anti-inflammatory treatment if anything does |
| S | Segmental glomerulosclerosis, S0 or S1 | Established scarring in part of the filtering units; argues for protecting what remains |
| T | Tubular atrophy and interstitial fibrosis, T0, T1 or T2 | The measure of irreversible loss, and the strongest single predictor of the long-term outcome |
| C | Crescents, C0, C1 or C2 by the proportion of glomeruli involved | Aggressiveness. A high C score means the disease can take function quickly and needs a different response |
Two ways of reading this score are worth stating, because patients are often given the letters without either. The first is that it is a profile, not a grade: E1T0 and E0T2 describe two different diseases that happen to share a name, and they justify different treatment. The second is that it is read once, while proteinuria and filtration are read forever — the biopsy tells us what has happened and what is still inflamed, and the two numbers tell us what is happening now.
The secondary causes that must be excluded
Before the label "primary IgA nephropathy" is applied, the plausible secondary drivers are looked for and excluded. This is not thoroughness for its own sake: several of them have a treatment that is more effective than anything the kidney-directed medicines offer, and immunosuppressing a person whose IgA deposition is driven by an untreated infection makes the situation worse.
| Cause to exclude | How it is looked for | What finding it changes |
|---|---|---|
| Chronic liver disease | Liver function tests, hepatitis serology, and a history of liver disease or alcohol use | The kidney management stays supportive; immune suppression is generally not the answer |
| Coeliac disease | Coeliac serology, with endoscopic confirmation where positive | A gluten-free diet becomes the treatment, and it can be the whole treatment |
| Inflammatory bowel disease | History of bowel symptoms; endoscopy where the history suggests it | Controlling the bowel disease is the kidney treatment |
| Chronic infection | Hepatitis B and C serology, HIV serology, and a review for other persistent infection | Immune therapy is deferred until the infection is treated |
| Systemic autoimmune disease, particularly lupus | Autoantibodies, complement, and the clinical picture | A different disease with a different treatment pathway — see lupus nephritis |
| A drug cause | A medicine review, including over-the-counter anti-inflammatories and supplements | Withdrawal of the agent, which costs nothing and sometimes resolves the picture |
Who genuinely needs a biopsy, and who does not
Not every person with blood in the urine needs a biopsy, and saying so is part of being useful. The procedure is recommended when its result would change what is done — and the result changes management in four situations: persistent proteinuria alongside the haematuria; a falling filtration rate; a presentation severe enough that aggressive treatment is being considered; and any picture in which an alternative diagnosis is plausible enough that treating it differently is realistic.
It can reasonably be deferred when the haematuria is microscopic and isolated, proteinuria is absent, filtration is normal and blood pressure is normal — a combination that describes a great many people found on routine screening. In that situation the sensible plan is periodic measurement rather than a procedure, with the biopsy revisited if protein appears or filtration moves. Thin basement membrane disease, which is familial and generally benign, falls into this category, and distinguishing it from early IgA nephropathy sometimes means watching rather than cutting.
There are also reasons to defer for a time rather than permanently: an active infection, uncontrolled blood pressure, a bleeding tendency, a single kidney, or a pregnancy. Each of these changes the risk calculus of the procedure without changing the question it would answer, and each is managed rather than accepted as a permanent exclusion.
The decision is best made with the whole picture in front of one clinician rather than in pieces: the urine microscopy, two or three protein measurements, a filtration trend, the blood pressure record, the secondary-cause screen, and the patient's own view of how much uncertainty they are willing to carry. That is the assessment described on the overview page, and it is the one we run from records before anyone travels.